KESTRA MEDICAL TECHNOLOGIES, LTD. Income Statement
KMTS / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Revenue increased 115.1% from FY2023 to FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | - | $59.8M | $27.8M |
| Cost of Revenue | - | $35.6M | $27.5M |
| Gross Profit | - | $24.2M | $362.0K |
| SG&A Expense | - | $114.9M | $69.9M |
| R&D Expense | - | $15.7M | $15.5M |
| Operating Income | - | -$106.4M | -$85.1M |
| Income Tax | - | $135.0K | $24.0K |
| Net Income | - | -$113.8M | -$94.1M |
| EPS (Basic) | -$5.07 | -$5.13 | -$5.07 |
| EPS (Diluted) | -$5.07 | -$5.13 | -$5.07 |
| Shares Outstanding | 105.8K | 24.6M | 19.9M |
| Gross Margin | - | 40.5% | 1.3% |
| Profit Margin | - | -190.3% | - |